U.S. Vaccine Market, By Product Type (Human Vaccine (Pediatric Vaccines, Adult & Adolescent Vaccines, Other Human Vaccines), Animal Vaccine (Livestock Vaccines, Companion Animal Vaccines, Other Animal Vaccines)), By End User (Hospitals, Clinics Vaccination, Centers)

Published In : Jul 2023

Code : CMI4011

Pages :176

Formats :

Excel and PDF

Industry : Biotechnology

Market Challenges And Opportunities

U.S. Vaccine Market: Restraint

High cost of refrigeration of vaccines

High cost of refrigeration of vaccines is expected to hinder the growth of the market. For vaccines, refrigeration is mandatory to prevent alteration of their chemical structure mainly due to contact with water and humidity resulting in ineffective medications. Maintaining this cold chain from production until they are used in treatment is a costly process accounting for about 80% of the price of vaccinations. For instance, The vaccine, developed by Pfizer and the German firm BioNTech, seems to provide 90% immunity according to early data released. The vaccine has to be stored at -70 degrees Celsius. freezers don’t get that cold, making distribution of this vaccine refrigeration which cost US$10,000 to US$15,000 each.

Market Players are taking initiative to launch cost-effective products.